Now that appears to have opened the door for Boston Scientific Chief Executive James Tobin James Tobin .
But Boston Scientific put the new, richer offer on the table only until 5 P.
Perhaps Tobin's most important task was to heal Boston Scientific's ailing cardiac stent business.
Within two years, Nicholas had handed most of Boston Scientific's day-to-day activities to his successor.
That ruling was a huge boon to Boston Scientific, but it doesn't clear the field entirely.
Boston Scientific's next model will be the meeting point of the medical device and drug businesses.
Boston Scientific also wants an injunction to prevent Israel-based Medinol from offering its technology to competitors.
Click here for a video with more from Ken Kam on why he likes Boston Scientific.
Boston Scientific said it plans to begin marketing the product in the U.S. immediately.
Boston Scientific Corporation had an annual average earnings growth of 0.9% over the past 10 years.
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices.
Several key management changes are designed to help Boston Scientific get back on a positive track.
"We're not positioning ourselves as lower-priced, " says Paul LaViolette , group president cardiovascular at Boston Scientific.
FORBES: Boston Scientific Close On J&J's Heels With New Stent
For two firms, Boston Scientific and Guidant , this research battle evolved into a nasty legal war.
Kam believes Boston Scientific has corrected the manufacturing problem and will continue to dominate the stent market.
Boston Scientific was once a spectacular growth story as the company exploited its early advantages in stents.
At Boston Scientific, the question is why is the guy who was supposed to fix things up leaving?
FORBES: Boston Scientific Turnaround Expert Quits Before The Turnaround
The most logical thing for Boston Scientific to do, Novarro says, is to buy growth by purchasing St.
In 2001, Guidant and Cook entered into a distribution agreement, which Boston Scientific successfully challenged in June 2002.
Right now, Conor is developing stents that deliver exactly the same drug used in the Boston Scientific stents.
Most analysts think investors should stand pat on Boston Scientific, with 15 of 22 analysts rating it hold.
When Guidant and Cook entered into the distribution agreement, Boston Scientific challenged it, saying that violated the original agreement.
Tyco Healthcare, Boston Scientific and tiny Rita Medical Systems make the equipment, which includes portable generators and single-use needles.
The results of a much-watched study comparing stents and drugs were revealed at a Boston Scientific meeting Sunday night.
Boston Scientific believes allowing Guidant to sell the paclitaxel-coated stent violates this agreement.
Cook subsequently entered into a distribution agreement with Guidant, which Boston Scientific claimed violated the co-exclusive agreement with Angiotech.
The rub: Guidant's partner, Cook , violated an earlier deal on the medical devices that also involved Boston Scientific.
Boston Scientific's drug-coated stent, Taxus, isn't expected to reach the market until 2004.
But then it will face competition from Boston Scientific (nyse: BSX - news - people ).
The manufacturer, now owned by Boston Scientific, faces 550 individual or class suits.
应用推荐